Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-08
DOI
10.1186/s12933-020-01197-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
- (2020) Shih-Chieh Shao et al. Cardiovascular Diabetology
- Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
- (2020) Lisa Ludwig et al. Cardiovascular Diabetology
- Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
- (2020) Angela Dardano et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
- (2020) José Luis Górriz et al. Journal of Clinical Medicine
- Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study
- (2020) Chun-Ting Yang et al. Cardiovascular Diabetology
- Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
- (2020) David Thein et al. Cardiovascular Diabetology
- Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
- (2020) Enrico Longato et al. Cardiovascular Diabetology
- Dapagliflozin and Cardiac, Kidney and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
- (2020) Marc P. Bonaca et al. CIRCULATION
- Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories – Insights from the EMPA‐REG OUTCOME trial
- (2020) Christoph Wanner et al. DIABETES OBESITY & METABOLISM
- SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes
- (2020) Kenta Nonomura et al. INTERNAL MEDICINE
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
- (2019) Kenneth W. Mahaffey et al. CIRCULATION
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2019) Rajiv Saran et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
- (2019) DIABETES CARE
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2018) Johannes F. E. Mann et al. CIRCULATION
- Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes
- (2018) Guozhi Jiang et al. KIDNEY INTERNATIONAL
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus
- (2017) Srikanth Yandrapalli et al. POSTGRADUATE MEDICINE
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- (2015) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease
- (2015) Konstantinos P. Imprialos et al. JOURNAL OF HYPERTENSION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of liraglutide on endothelial function in patients with type 2 diabetes
- (2014) Debashis Nandy et al. Diabetes & Vascular Disease Research
- Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes
- (2014) Julie A. Lovshin et al. DIABETES CARE
- Effects of GLP-1 on appetite and weight
- (2014) Meera Shah et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent
- (2013) Alexandrios Briasoulis et al. Current Cardiology Reports
- Exenatide Exerts a Potent Antiinflammatory Effect
- (2011) Ajay Chaudhuri et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search